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Abstract
Lung tumor progression is regulated by proangiogenic factors. Heat shock protein
A12B (HSPA12B) is a recently identified regulator of expression of proangiogenic
factors. However, whether HSPA12B plays a role in lung tumor growth is unknown.
To address this question, transgenic mice overexpressing HSPA12B (Tg) and wildtype littermates (WT) were implanted with Lewis lung cancer cells to induce lung
tumorigenesis. Tg mice showed significantly higher number and bigger size of tumors
than WT mice. Tg tumors exhibited increased angiogenesis and proliferation while
reduced apoptosis compared with WT tumors. Interestingly, a significantly enhanced
upregulation of Cox-2 was detected in Tg tumors than in WT tumors. Also, Tg tumors
demonstrated upregulation of VEGF and angiopoietin-1, downregulation of AKAP12,
and increased eNOS phosphorylation compared with WT tumors. Celecoxib, a selective
Cox-2 inhibitor, suppressed the HSPA12B-induced increase in lung tumor burden.
Moreover, celecoxib decreased angiogenesis and proliferation whereas increased
apoptosis in Tg tumors. Additionally, celecoxib reduced angiopoietin-1 expression and
eNOS phosphorylation but increased AKAP12 levels in Tg tumors. Our results indicate
that HSPA12B stimulates lung tumor growth via a Cox-2-dependent mechanism. The
present study identified HSPA12B as a novel facilitator of lung tumor growth and a
potential therapeutic target for the treatment of lung cancer.

Introduction

Heat shock protein A12B (HSPA12B) is a distant
member of the mammalian heat shock protein 70 (Hsp70)
family because HSPA12B contains an atypical Hsp70
ATPase domain [3]. HSPA12B is expressed specifically
in endothelial cells, which differs from the ubiquitous
expression of other Hsp70 family members such as
HSPA1A, HSPA1B, HSPA5 and HSPA8 [4-7]. This unique
distribution pattern suggests the possible involvement of
HSPA12B in the pathogenesis of endothelium-associated
events. Indeed, previous studies from our group show
that overexpression of HSPA12B protects the heart and
brain from ischemic injury [5, 8]. Moreover, HSPA12B

Lung cancer is the leading cause of cancerrelated death in humans worldwide, with an overall 5
year survival rate of approximately 15% [1, 2]. Despite
advances in the diagnosis and treatment of lung cancer,
only modest improvements in patient survival have been
achieved in the past 25 years [1, 2]. A better understanding
of the mechanisms underlying lung cancer development
and progression is urgently needed for the design of novel
therapeutic modalities such as molecular targeted therapies
for the treatment of this disease.
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attenuates cardiac injury during endotoxemia [7]. These
effects of HSPA12B are mediated by the regulation of
the expression of proangiogenic factors such as Cox-2,
VEGF, angiopoietin-1 (Ang-1) and eNOS [5-9], which
play important roles in tumor progression [1, 2, 10, 11].
However, whether HSPA12B participates in lung cancer
growth is unknown.
To address this question, a lung cancer model was
generated by implanting Lewis lung cancer cells (LLCs)
into transgenic mice overexpressing the HSPA12B gene
(Tg) and wild-type control mice (WT). Overexpression
of HSPA12B stimulated lung tumor growth, and this
effect was mediated by Cox-2-dependent increases of
angiogenesis and cell proliferation and decrease of cell
apoptosis in lung tumors. The present study identified
HSPA12B as a novel facilitator of lung tumor growth,
which suggests that targeting HSPA12B could be a

therapeutic strategy for the treatment of lung cancer.

Results
HSPA12B is expressed in pulmonary endothelial
cells
To investigate the roles of HSPA12B in lung cancer
progression, we generated HSPA12B Tg mice. As shown
in Figure 1A, HSPA12B protein levels were significantly
higher (212.6%) in Tg lung tissues than in WT controls
(P < 0.01). Immunofluorescence staining showed that
HSPA12B (green) in Tg lung sections colocalized with
PCAM-1 (red), a marker of endothelial cells (Figure
1B). Collectively, the results suggest that HSPA12B was

Figure 1: Endothelial HSPA12B facilitated lung tumor growth. (A) Immunoblotting for HSPA12B. Lung tissues from WT
and Tg mice (8-week old) were prepared for immunoblotting for HSPA12B. The same membrane was blotted with α-Tubulin to serve
as a loading control. *P<0.01, n=6 per group. (B) Immunofluorescence for HSPA12B. Lung tissues from Tg mice (8-week old) were
prepared for cryosectioning. The immunofluorescence staining for HSPA12B and PCAM-1 was performed. Note that HSPA12B (FITC)
was colocalized with PCAM-1 (Cy3). Representative images from three independent experiments are shown. (C) Tumor formation. WT
and Tg mice were implanted with LLCs to induce lung tumorigenesis. Lung tumor formation was examined and photographed 18 days
after LLCs implantation. Note that Tg mice had a higher number and bigger size of tumors than WT mice. n=7- 9 per group. (D) Tumor
number. WT and Tg mice were implanted with LLCs to induce lung tumorigenesis. Eighteen days later, the tumors were isolated from
lungs for tumor number counting. *P<0.01, n=7- 9 per group. (E) Tumor Burden. WT and Tg mice were implanted with LLCs to induce
lung tumorigenesis. Eighteen days later, the tumors were isolated from lungs for tumor burden weighing. *P<0.01, n=7- 9 per group. All
quantitative data are expressed as means ± SD.
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HSPA12B inhibits apoptosis in lung tumors

overexpressed in pulmonary endothelial cells in Tg mice.

HSPA12B facilitates lung tumor growth

Apoptosis of tumor cells is an important determinant
of tumor load [12]. We therefore examined apoptosis in
lung tumors by TUNEL staining. As shown in Figure 3A,
the rate of apoptosis was 4.9% in WT tumors and 2.7% in
Tg tumors. Interestingly, the rate of apoptosis was 45.8%
lower in Tg than in WT tumors (P < 0.01).
Figure 3B shows the levels of expression of the
antiapoptotic protein Bcl-2 and the proapoptotic protein
Bax in lung tumors. The lung tissues from salinetreated mice served as normal controls. Bcl-2 and Bax
levels were comparable between WT tumors and WT
controls. However, a significant increase in Bcl-2 levels
and decrease in Bax levels was detected in Tg tumors
compared with Tg controls (P < 0.01). Importantly, Bcl-2
levels were significantly higher by 52.2% and Bax levels
were significantly lower by 36.2% in Tg tumors than in
WT tumors (P < 0.01). No significant difference in Bcl2 or Bax levels was observed between the two normal
controls.

Lung tumorigenesis was induced by implantation
with LLCs by caudal vein injection in Tg and WT mice.
Tumor formation was analyzed 18 days after LLCs
implantation. As shown in Figure 1C, Tg mice had a
higher number and bigger size of tumors than WT mice.
The average tumor number was 28 in Tg and 17 in WT
mice (Figure 1D). The tumor burden was 0.493 g in Tg
and 0.285 g in WT mice (Figure 1E). Therefore, tumor
number and tumor burden were 64.9% and 73.3% higher,
respectively, in Tg than in WT mice (P < 0.01).

HSPA12B increases angiogenesis in lung tumors
Angiogenesis in lung tumors was evaluated by
immunostaining for PCAM-1. As shown in Figure 2, the
percentage of PCAM-1-positive areas was 4.8% in WT
tumor and 7.1% in Tg tumors. Thus, 49.3% more PCAM1 positive areas were presented in Tg tumors than that in
WT tumors (P < 0.01).

HSPA12B increases tumor cell proliferation
To determine the role of tumor cell proliferation in
the HSPA12B stimulation of lung tumor growth, cells were

Figure 2: HSPA12B increased angiogenesis in lung tumors. Lung tumor tissues were collected 18 days after LLCs implantation.

Cryosections were prepared for immunostaining for PCAM-1. Hoechst 33342 was used to counter staining nuclei. The fluorescence images
in tumors was observed and captured using a fluorescent microscope at a magnification of 400 ×. The quantitative data are expressed as
means ± SD. *P<0.01, n=4-5 per group.
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Figure 3: HSPA12B suppressed apoptosis in lung tumors. Lung tumor tissues were collected 18 days after LLCs implantation
for the following experiments. (A) TUNEL assay. Paraffin-embedded sections were prepared. A TUNEL assay was performed to detect
apoptosis. Hoechst 33342 reagent was used to counterstain the nuclei. TUNEL-positive cells in tumors were observed using a fluorescent
microscope at a magnification of 400 ×. *P<0.01, n=3-4 per group. (B) Immunoblotting analysis for Bcl-2 and Bax. Protein extracts were
prepared for immunoblotting for Bcl-2 and Bax. The same membrane was blotted with α-Tubulin to serve as a loading control. *P<0.01,
n=4-6 per group. All quantitative data are expressed as means ± SD.

Figure 4: HSPA12B increased cell proliferation in lung tumors. Lung tumor tissues were collected 18 days after LLCs
implantation for paraffin-embedded sectioning. Slides were subjected to immunofluorescence staining for Ki-67 (Cy3, red). Hoechst 33342
reagent was used to counterstain the nuclei. Images were observed using a fluorescent microscope at a magnification of 400×. Higher
magnification images of the boxed areas are shown in the down panels. The quantitative data are expressed as means ± SD. #P<0.05, n=4
per group.
www.impactjournals.com/oncotarget
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stained with Ki-67 as an indicator of cell proliferation and
analyzed by immunofluorescence. The percentage of Ki67-positive cells was 16.8% higher in Tg tumors than in
WT tumors (80.2 ± 5.4 % vs. 68.7 ± 5.0 %, P < 0.05)
(Figure 4).

16], were significantly lower in Tg tumors than in normal
Tg lung tissues (P < 0.05) (Figure 4A). Moreover, Tg
tumors exhibited significantly lower levels of AKAP12 by
38.5% compared with WT tumors (P < 0.05). AKAP12
levels were slightly lower in WT tumors than in normal
WT lung tissues, although the difference did not reach
statistical significance.

HSPA12B upregulates the expression of VEGF
and Ang-1 and increases the phosphorylation of
eNOS in lung tumors

HSPA12B enhances Cox-2 upregulation in lung
tumors

We recently reported that HSPA12B upregulates the
expression of proangiogenic factors (e.g., VEGF, Ang1 and eNOS) in the ischemic myocardium [5]. Because
these proangiogenic factors play important roles in the
regulation of angiogenesis, apoptosis proliferation [5,
10, 13, 14], their expression levels were examined in
lung tumors. As shown in Figure 5A, the levels of VEGF,
Ang-1 and eNOS were significantly increased in both
WT and Tg tumors compared with the genotype-matched
normal controls (P < 0.01 or P < 0.05), with significantly
higher levels of VEGF and Ang-1 (16.7% and 78.2%,
respectively) in Tg than in WT tumors (P < 0.01).
Although eNOS levels were comparable between WT and
Tg tumors, phospho-eNOS (p-eNOS) levels were 37.0%
higher in Tg tumors than in WT tumors (P < 0.05).

Cox-2 plays critical roles in lung tumor progression
[12, 17]. As shown in Figure 5B, Cox-2 levels were
increased by 43.3% in WT tumors and 129.1% in Tg
tumors compared with the genotype-matched normal
lungs (P < 0.01 or P < 0.05), and they were 51.6% higher
in Tg tumors than in WT tumors (P < 0.01) (Figure 5B).
No significant difference in the Cox-2 level was observed
between normal WT and Tg lungs.

Inhibition of Cox-2 with celecoxib abolishes the
HSPA12B-induced facilitation of lung tumor
growth
To further examine the role of Cox-2 in the
HSPA12B-induced facilitation of lung tumor growth,
mice were treated with the selective Cox-2 inhibitor
celecoxib after LLCs implantation. As shown in Figure
6A, tumor size was reduced in WT and Tg mice treated
with celecoxib compared to the corresponding tumors in
untreated mice. Tumor burden was significantly decreased

HSPA12B decreases AKAP12 levels in lung
tumors
The levels of A kinase anchor protein 12
(AKAP12), which exerts tumor suppressor activity [15,

Figure 5: HSPA12B upregulated the expression of Cox-2, VEGF and Ang-1, increased the phosphorylation of eNOS,
while decreased expression of AKAP12 in lung tumors. Lung tumor tissues were collected 18 days after LLCs implantation.
Protein extracts were prepared for immunoblotting with the indicated antibodies. The same membrane was blotted with α-Tubulin to serve
as a loading control. All quantitative data are expressed as means ± SD. *P<0.01 and #P<0.05, n=4-6 per group.
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Figure 6: Cox-2 inhibitor celecoxib suppressed HSPA12B-induced stimulation of lung tumor growth. WT and Tg mice
were administrated with celecoxib (cele), a selective inhibitor for Cox-2, after LLCs implantation. Lungs were isolated and photographed
18 days after LLCs implantation. Representative images from six independent experiments are shown (A). Tumors were subsequently
isolated from lungs for tumor burden weighing (B). The quantitative data are expressed as means ± SD. *P<0.01, n=6 per group.
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Figure 7: Cox-2 inhibitor celecoxib reduced angiogenesis and proliferation, and increased apoptosis in Tg lung tumors.

(A) Tg mice were administrated with celecoxib (cele) after LLCs implantation. Lung tumor tissues were collected 18 days after LLCs
implantation for the following experiments. Angiogenesis. Cryosections were prepared for immunostaining against PCAM-1. Hoechst
33342 reagent was used to counterstain the nuclei. PCAM-1-positive areas in tumors were observed and calculated using a fluorescent
microscope at a magnification of 400 ×. *P<0.01, n=4 per group. (B) TUNEL assay. Paraffin-embedded sections were prepared. A TUNEL
assay was performed to detect apoptosis. Hoechst 33342 reagent was used to counterstain the nuclei. TUNEL-positive cells in tumors
were observed using a fluorescent microscope at a magnification of 400 ×. *P<0.01, n=3-4 per group. (C) Immunoblotting for Bcl-2 and
Bax. Protein extracts were prepared for immunoblotting for Bcl-2 and Bax. The same membrane was blotted with α-Tubulin to serve as
a loading control. *P<0.01, n=4-8 per group. (D) Immunofluorescence staining for Ki-67. Paraffin-embedded sections were subjected to
immunofluorescence staining for Ki-67 (Cy3, red). Hoechst 33342 reagent was used to counterstain the nuclei. Images were observed
using a fluorescent microscope at a magnification of 400×. Higher magnification images of the boxed areas are shown in the down panels.
*P<0.01, n=4 per group. All quantitative data are expressed as means ± SD.
www.impactjournals.com/oncotarget
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Celecoxib suppresses cell proliferation in Tg
tumors

by 72.0% in WT and 87.0% in Tg mice following
celecoxib administration compared with the corresponding
untreated tumors (P < 0.01) (Figure 6B). Importantly,
no significant difference in tumor burden was observed
between WT and Tg tumors following celecoxib treatment
(0.080 ± 0.041 g vs. 0.064 ± 0.054 g, P > 0.05). These
results suggest that celecoxib abolished the HSPA12Binduced facilitation of lung tumor growth.

Figure 7D shows the rate of Ki-67-positive cells
in Tg lung tumors treated with or without celecoxib.
Celecoxib treatment significantly decreased the percentage
of Ki-67-positive cells in Tg tumors by 34.9% compared
with that in untreated Tg tumors (P < 0.01).

Celecoxib decreases angiogenesis in Tg tumors

Celecoxib reduces Ang-1 expression and eNOS
phosphorylation in Tg tumors

As shown in Figure 7A, celecoxib treatment
significantly decreased PCAM-1-positive areas by 48.2%
in Tg tumors compared with untreated Tg tumors (3.48 ±
0.76% vs. 7.11 ± 0.15%, P < 0.01).

As shown in Figure 8, Ang-1 levels were
significantly reduced by 73.9% in Tg tumors treated with
celecoxib compared with untreated Tg tumors (P < 0.01),
whereas celecoxib had no significant effect on VEGF and
eNOS expression. The levels of phosphorylated eNOS
in Tg tumors were significantly reduced by 37.6% by
celecoxib treatment compared with that in untreated Tg
tumors (P < 0.01). Celecoxib administration significantly
reduced Cox-2 levels by 18.4% in Tg tumors (P < 0.05).

Celecoxib increases cell apoptosis in Tg tumors
As shown in Figure 7B, a 360.5% increase in the
rate of apoptosis was observed in Tg tumors treated with
celecoxib compared with untreated Tg tumors (P < 0.01).
The levels of Bcl-2 decreased significantly by 52.0%
whereas Bax levels increased by 34.4% in Tg tumors
treated with celecoxib compared with untreated Tg tumors
(P < 0.01) (Figure 7C).

Figure 8: Cox-2 inhibitor celecoxib decreased Ang-1 expression, reduced eNOS activation, and increased AKAP12
expression in Tg lung tumors. Tg mice were administrated with celecoxib (cele) after LLCs implantation. Tumor tissues were

collected 18 days after LLCs implantation for immunoblotting analysis with the indicated antibodeis. The same membrane was blotted
with α-Tubulin to serve as a loading control. All quantitative data are expressed as means ± SD. *P<0.01, n=4-8 per group.
www.impactjournals.com/oncotarget
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Celecoxib increases AKAP12 expression in Tg
tumors

growth and progression of lung cancer.
HSPA12B Tg lung tumors showed a significantly
decreased rate of apoptosis, which was negatively
correlated with lung tumor growth. This was supported
by an increase in Bcl-2 levels and a decrease in Bax
levels in Tg tumors compared with those in WT tumors.
Apoptosis is an important mechanism limiting lung tumor
progression [26-28]. For example, failure to efficiently
induce apoptosis contributes to cisplatin resistance in lung
cancer [27]. On the other hand, apoptosis sensitization
mediates the tumor suppressor effects of rapamycin,
decitabine and vorinostat [26, 28]. Taken together,
our results indicate that the suppression of apoptosis
contributed to the HSPA12B-induced growth of lung
tumors.
The proliferation rate of cancer cells is positively
correlated with tumor progression [26, 29, 30]. An
increased proliferation rate is associated with the CD97promoted progression of thyroid cancer, whereas the
suppression of tumor cell proliferation mediates the
inhibitory effects of PDE4i on tumor xenograft growth
[31, 32]. In the present study, Tg lung tumors showed
an increased proliferation rate compared to WT tumors,
as indicated by the Ki-67 positive staining. Collectively,
these results suggest that the increase in cell proliferation
contributed to the growth of Tg lung tumors.
Apoptosis and proliferation of cancer cells are
regulated by proangiogenic factors such as Cox-2, VEGF,
Ang-1 and eNOS [1, 11, 33-35]. Ho et al. showed that
suppression of Cox-2 activity mediates the IL-27induced reduction of proliferation and restriction of
lung tumorigenicity [1]. Baek et al. reported that VEGF
enhances tumor survivability via suppression of apoptosis
[10]. Human lung carcinoma tissues have significantly
higher levels of Ang-1 and its receptor Tie2 than adjacent
noncancerous tissues [36]. Moreover, eNOS has been
shown to protect prostate cancer cells from TRAILinduced apoptosis [35]. In the present study, the levels
of Cox-2, VEGF, Ang-1 and phosphorylated eNOS were
significantly higher in Tg lung tumors than in WT lung
tumors. Consistent with these results, we recently reported
that overexpression of HSPA12B upregulates VEGF and
Ang-1 in ischemic hearts, and HSPA12B upregulates
Ang-1 expression in ischemia/reperfusion brains and
endotoxemic hearts [5, 7, 8, 35]. Taken together, these
findings suggest that proangiogenic factors are involved
in the HSPA12B-induced decrease in apoptosis and
increase in cell proliferation in lung tumors, which in turn
promoted lung tumor growth.
Cox-2 plays critical roles in lung tumor progression
[12, 17]. We observed that HSPA12B enhanced Cox2 upregulation in lung tumors. To determine the role of
upregulated Cox-2 in the HSPA12B-induced stimulation
of lung tumor growth, mice were treated with the selective
Cox-2 inhibitor celecoxib after LLCs implantation.
Celecoxib significantly reduced tumor burden in both

In contrast to the effects of celecoxib on Ang-1
expression, AKAP12 expression levels were increased by
91.2% in Tg tumors treated with celecoxib compared with
untreated Tg tumors (P < 0.01) (Figure 8).

Discussion
In the present study, we showed that HSPA12B
in pulmonary endothelial cells stimulated lung cancer
growth in mice by enhancing angiogenesis, increasing cell
proliferation, and suppressing apoptosis in tumors via a
Cox-2-dependent mechanism.
Recent evidence demonstrates that tumor growth
is regulated by the cross-talk between endothelial cells
and tumor cells [18, 19]. As an example, lung carcinoma
cells when co-cultured with endothelial cells modify
their cellular molecular features that encourage tumor
cell survival through an undefined mechanism [18].
Knockdown of endothelial Dll4 stimulates the xenograft
tumor growth of lung cancer cells through promoting the
proliferation of neighboring cancer cells, and vice versa
[19]. Acute depletion of endothelial β3-integrin transiently
inhibits tumor growth and angiogenesis in mice [20].
Moreover, inhibition of endothelial FAK activity prevents
tumor metastasis by enhancing barrier function [21]. These
observations suggest an important role of endothelial
events in the regulation of lung tumor progression. In this
study, we provided first evidence for that HSPA12B, which
expresses predominantly in endothelial cells, stimulated
lung tumor growth as reflected by a significant increase in
tumor number and tumor burden.
Solid tumor growth and progression is dependent
on tumor-associated angiogenesis [22, 23]. Therefore,
angiogenesis is a promising target for lung cancer.
The only antiangiogenic agent currently approved for
the treatment of lung cancer is the VEGF monoclonal
antibody bevacizumab. However, bevacizumab only
modestly improved survival time (2 months) in patients
with advanced non-small cell lung cancer. Moreover,
bevacizumab use was associated with increased
treatment-related death [22, 24, 25]. Thus, further
development of novel antiangiogenic strategies for lung
cancer is strongly needed. In this study, we observed that
HSPA12B increased angiogenesis in lung tumors, which
showed positive correlations with lung tumor growth.
In supporting this observation, previous studies by ours
and others have demonstrated that HSPA12B increased
tube formation in endothelial cells and angiogenesis
in myocardium post-infarction [5, 9, 25]. Collectively,
HSPA12B is a facilitator of lung cancer-associated
angiogenesis. Further studies are needed to investigate
whether targeted suppressing HSPA12B would limit the
www.impactjournals.com/oncotarget
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that supplied them were as follows: Bcl-2, Bax, Cox-2
and p-eNOS (Cell Signaling Technology, Beverly, MA);
PCAM-1 and Ki-67 (BD Pharmingen, San Jose, CA);
eNOS (BD Biosciences, Bedford, MA); and VEGF, Ang1 and AKAP12 (Abcam, Cambridge, UK). Celecoxib was
obtained from Pfizer Pharmaceuticals LLC (Barceloneta,
PR). The TUNEL assay kit was from Promega (Madison,
WI). The supersignal west pico chemiluminescent
substrate was obtained from Pierce (Rockford, IL).

WT and Tg mice. Most importantly, tumor burden was
comparable between celecoxib-treated WT and celecoxibtreated Tg mice, suggesting that Cox-2 inhibition
completely suppressed HSPA12B-induced tumor growth.
In addition, the HSPA12B-induced increase in cell
proliferation and decrease in apoptosis in lung tumors
was abolished by Cox-2 inhibition. Furthermore, Cox-2
inhibition decreased Ang-1 expression levels, suppressed
eNOS phosphorylation levels, and increased AKAP12
expression levels in HSPA12B Tg tumors compared to
those in untreated Tg tumors. Previous studies showed that
Cox-2 inhibition decreases Ang-1 expression in U-87MG
cells and eNOS activation in damaged kidneys, which is
consistent with the present results [37, 38]. Taken together,
our results suggest that the HSPA12B-induced stimulation
of lung tumor growth was mediated by Cox-2.
So far there is no direct evidence showing how
HSPA12B regulates the expression of Cox-2,VEGF,
Ang-1 and eNOS. However, evidence has suggested that
AKAP12 may play a role in this regulation based on
the following reasons. Firstly, AKAP12 has been shown
to interact directly with HSPA12B on a yeast 2-hybrid
system [9]. Secondly, AKAP12 is a kinase-scaffolding
protein possessing angiogenic inhibition characters [39].
Overexpression of AKAP12 disrupts endothelial tube
formation in Matrigel substrates, and vice versa [39].
Thirdly, AKAP12 negatively regulates the expression
of VEGF, Ang-1 and eNOS [40, 41], which could be
mediated by a downregulation of HIf-1α. Finally, though
no direct evidence showing how HSPA12B regulates Cox2 expression, VEGF may be involved in. Shtivelband and
his colleagues have reported that administration of VEGF
stimulated Cox-2 expression in human endothelial cells
[42]. Consistent with this observation, other studies also
demonstrated that VEGF serves as a regulator of Cox2 expression [43]. On the other hand, Cox-2 can affect
VEGF Production [44]. It is possible that HSPA12B
downregulated AKAP12, which in turn increased VEGF
expression and thereby stimulated Cox-2 expression.
In summary, the present study showed for the first
time that HSPA12B promotes lung tumor growth through
a mechanism involving Cox-2. Our data indicates that
HSPA12B could be an alternative therapeutic target for
the suppression of lung cancer progression.

Animals
Investigation has been conducted in accordance with
the ethical standards and according to the national and
international guidelines and has been approved by Nanjing
University review board. Transgenic mice overexpressing
the human hspa12b gene (Tg) driven by its own promoter
were developed as described in our previous studies [5,
7]. Male littermates of HSPA12B Tg mice and wild type
(WT) mice at 8-10 week of age were used in the present
study. Mice were bred and maintained at the Model
Animal Research Center of Nanjing University and
maintained in the Animal Laboratory Resource Facility at
Nanjing University.

Lung tumorigenesis induction
Lung tumorigenesis in mice was induced by
implantation with LLCs. LLCs were obtained from ATCC
and maintained in DMEM supplemented with 10% FCS.
LLCs were collected from 85% confluence cultures
and implanted into mice (1.5 × 105 cells/mice) via tail
intravenous injection. The saline-injected mice served
as normal controls. Lung tumor formation was evaluated
18 days after LLCs implantation. Briefly, the mice were
sacrificed by an overdose of anesthesia (pentobarbital
sodium 150 mg/kg, intraperitoneal injection) and cervical
dislocation. Lungs were isolated and photographed after
thoracotomy. Subsequently, the tumors were isolated from
the lungs, counted and weighed.
For Cox-2 inhibition experiments, WT and Tg mice
were fed with chows containing celecoxib (1.5 g/kg chow)
after LLCs transplantation until the experiments were
completed according to previously described methods
[45].

Materials and Methods

Immunofluorescence staining

Antibodies and chemicals

For examination of colocalization of HSPA12B
and PCAM-1, immunofluorescence experiments were
performed following previously described protocols [5,
7]. Briefly, lung tissues were collected from adult Tg
mice and prepared for cryosectioning. After blocking
with 3.5% normal goat serum for 30 min, the cryosections

Primary antibody against α-Tubulin was purchased
from Sigma-Aldrich (St Louis, MO). The primary
antibody against HSPA12B was a generous gift from
Dr. Zhihua Han (East Tennessee State University) [9].
The remaining primary antibodies and the companies
www.impactjournals.com/oncotarget
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were incubated with the appropriate primary antibodies
overnight, washed and incubated with FITC- and/or Cy3labelled secondary antibodies for 60 min. The sections
were observed under a fluorescent microscope (Zeiss Ltd.,
Oberkochen, Germany) at a magnification of 400×.
For evaluation of angiogenesis in lung tumors,
immunofluorescence staining for PCAM-1 was performed
on cryosections of lung tumor tissues which were collected
18 days after LLCs implantation. The staining protocol
was as same as mentioned above. The PCAM-1-positive
staining in tumors was observed using a fluorescent
microscope at a magnification of 400× .The percentages
of PCAM-1-positive areas in more than six randomly
selected tumor fields of each sample were measured using
a computerized software (Olympus, Japan).
For evaluation of cell proliferation in lung tumors,
immunofluorescence staining for Ki-67 was performed
following previously described protocols with a minor
modification [46]. Briefly, lung tumor tissues were
collected 18 days after LLCs implantation and prepared for
paraffin-embedded sectioning. Slides were deparaffinized
and microwaved to retrieve antigen. After blocking with
3.5% normal goat serum, the cryosections were incubated
with primary antibody for Ki-67 overnight followed by
incubation with Cy3-labelled secondary antibody. Hoechst
33342 reagent was used to counterstain the nuclei. The
number of Ki-67-positive cells in tumors was counted in
more than six randomly selected fields using a fluorescent
microscope at a magnification of 400× (Zeiss Ltd.
Oberkochen, German). The percentage of Ki-67-stained
nuclei over total nuclei was calculated.

signals were detected by enhanced chemiluminescence.
To control for lane loading, the same membranes were
probed with anti-α-Tubulin. The signals were quantified
by scanning densitometry and the results from each
experimental group were expressed as relative integrated
intensity compared with that of controls.
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